The IASLC Lung Cancer News (ILCN) is the IASLC's official news medium for thoracic oncology specialists around the globe. ILCN provides its international audience with timely and relevant lung cancer news on topics across specialties and interests, such as novel clinical trial design and statistics, overcoming barriers to NGS testing, tobacco control and smoking/vaping cessation, patient-driven research, patient communication and care delivery during COVID, and more. Only the IASLC—the only international association dedicated to the study of lung cancer—can bring you multidisciplinary nuanced perspectives on daily clinical conundrums and the latest novel research by the true experts in the field.
Featured
New Forum to Discuss Molecular Challenges
When the initial molecular report suggested a ROS1 rearrangement, crizotinib was started in expectation of a typically great response. However, when the first on-treatment scan showed an increase in the size of the lung cancer it became obvious that this case was far from typical. Moderated by Dr. D. Ross Camidge, who provided a remote second opinion on the case, the patient, Mr. Bill Brand, and his primary oncologist, Dr. Ron Natale, discuss the twists and turns in the diagnosis and provide crucial insights on the nuances of understanding molecular testing, the best way to use and not abuse remote second opinions, and how you can and should rapidly adapt a plan that isn’t working. Mr. Brand, who had to join one molecularly specific patient support group, leave and then join another different one, also provides advice for patients regarding self-advocacy and handling direct communication with physicians.
Meeting News
Evolving Standards of Care
Radiation Oncology
Industry News & Regulatory Approvals
Nursing & Allied Health
Names and News
Podcasts
Press Releases
The IASLC and ILCN would like to thank AstraZeneca and Daiichi Sankyo for their support.